Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

BRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF Mutations Between Primary and Corresponding Lymph Node Metastases.

Fakhruddin N, Jabbour M, Novy M, Tamim H, Bahmad H, Farhat F, Zaatari G, Aridi T, Kriegshauser G, Oberkanins C, Mahfouz R.

Sci Rep. 2017 Jul 5;7(1):4666. doi: 10.1038/s41598-017-04948-3.

2.

TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease.

Melo M, Gaspar da Rocha A, Batista R, Vinagre J, Martins MJ, Costa G, Ribeiro C, Carrilho F, Leite V, Lobo C, Cameselle-Teijeiro JM, Cavadas B, Pereira L, Sobrinho-Simões M, Soares P.

J Clin Endocrinol Metab. 2017 Jun 1;102(6):1898-1907. doi: 10.1210/jc.2016-2785.

PMID:
28323937
3.

Relevance of BRAF and NRAS mutations in the primary tumor and metastases of papillary thyroid carcinomas.

Cañadas-Garre M, Becerra-Massare P, Moreno Casares A, Calleja-Hernández MÁ, Llamas-Elvira JM.

Head Neck. 2016 Dec;38(12):1772-1779. doi: 10.1002/hed.24517. Epub 2016 Jun 14.

PMID:
27299298
4.

Highly Concordant Key Genetic Alterations in Primary Tumors and Matched Distant Metastases in Differentiated Thyroid Cancer.

Sohn SY, Park WY, Shin HT, Bae JS, Ki CS, Oh YL, Kim SW, Chung JH.

Thyroid. 2016 May;26(5):672-82. doi: 10.1089/thy.2015.0527.

PMID:
26971368
5.

The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases.

Eloy C, Santos J, Soares P, Sobrinho-Simões M.

Virchows Arch. 2011 Sep;459(3):265-76. doi: 10.1007/s00428-011-1133-7. Epub 2011 Jul 28.

PMID:
21796448
6.

Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.

Zou M, Baitei EY, Alzahrani AS, BinHumaid FS, Alkhafaji D, Al-Rijjal RA, Meyer BF, Shi Y.

Thyroid. 2014 Aug;24(8):1256-66. doi: 10.1089/thy.2013.0610. Epub 2014 Jun 10.

7.

BRAF and RAS Mutational Status in Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features and Invasive Subtype of Encapsulated Follicular Variant of Papillary Thyroid Carcinoma in Korea.

Kim M, Jeon MJ, Oh HS, Park S, Kim TY, Shong YK, Kim WB, Kim K, Kim WG, Song DE.

Thyroid. 2018 Apr;28(4):504-510. doi: 10.1089/thy.2017.0382. Epub 2018 Mar 16.

PMID:
29439609
8.

Application of BRAF, NRAS, KRAS mutations as markers for the detection of papillary thyroid cancer from FNAB specimens by pyrosequencing analysis.

Park SJ, Sun JY, Hong K, Kwak JY, Kim EK, Chung WY, Choi JR.

Clin Chem Lab Med. 2013 Aug;51(8):1673-80. doi: 10.1515/cclm-2012-0375.

PMID:
23585181
9.

Association between BRAF V600E mutation and regional lymph node metastasis in papillary thyroid carcinoma.

Lu J, Gao J, Zhang J, Sun J, Wu H, Shi X, Teng L, Liang Z.

Int J Clin Exp Pathol. 2015 Jan 1;8(1):793-9. eCollection 2015.

10.

[Invasiveness of papillary thyroid microcarcinoma with BRAF mutation].

Yang X, Liang ZY, Meng C, Liang J, Yu Z, Lin YS.

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2013 Aug;35(4):398-403. doi: 10.3881/j.issn.1000-503X.2013.04.008. Chinese.

11.

Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors.

Shi C, Guo Y, Lv Y, Nanding A, Shi T, Qin H, He J.

PLoS One. 2016 Dec 9;11(12):e0167414. doi: 10.1371/journal.pone.0167414. eCollection 2016.

12.

Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis with ARMS PCR.

Zhang J, Yang Y, Zhao J, Shi L, Xu Y, Yu K, Guo C.

Pathol Res Pract. 2019 Apr;215(4):761-765. doi: 10.1016/j.prp.2019.01.006. Epub 2019 Jan 19.

PMID:
30819583
13.

[Clinical pathological characteristics of resectable papillary thyroid microcarcinoma].

Shi CL, Guo Y, Lyu YC, Nanding ZABYS, Gao WC, Shi TF, Qin HD, Liu SY.

Zhonghua Zhong Liu Za Zhi. 2017 May 23;39(5):361-366. doi: 10.3760/cma.j.issn.0253-3766.2017.05.008. Chinese.

PMID:
28535653
14.

Associations of the BRAF(V600E) mutation with sonographic features and clinicopathologic characteristics in a large population with conventional papillary thyroid carcinoma.

Park AY, Son EJ, Kim JA, Youk JH, Park YJ, Park CS, Chang HS.

PLoS One. 2014 Oct 22;9(10):e110868. doi: 10.1371/journal.pone.0110868. eCollection 2014.

15.

High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes.

Vasko V, Hu S, Wu G, Xing JC, Larin A, Savchenko V, Trink B, Xing M.

J Clin Endocrinol Metab. 2005 Sep;90(9):5265-9. Epub 2005 Jul 5.

PMID:
15998781
16.

The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors.

Choi SY, Park H, Kang MK, Lee DK, Lee KD, Lee HS, Kim SW, Lee EN, Hong JC.

World J Surg Oncol. 2013 Nov 14;11:291. doi: 10.1186/1477-7819-11-291.

17.

Single Point Mutations in Pediatric Differentiated Thyroid Cancer.

Alzahrani AS, Murugan AK, Qasem E, Alswailem M, Al-Hindi H, Shi Y.

Thyroid. 2017 Feb;27(2):189-196. doi: 10.1089/thy.2016.0339. Epub 2016 Dec 20.

PMID:
27824297
18.

[Study on the correlation between BRAF(V600E) mutation and lymphatic metastases in papillary thyroid cancer staged preoperativelv as N0].

Gao Q, Zhang W, Wang N, Duan H, Zhou Y, Zhang W, Zhao D.

Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2015 Dec;29(23):2048-52. Chinese.

PMID:
27101676
19.

The thyroid imaging reporting and data system on US, but not the BRAFV600E mutation in fine-needle aspirates, is associated with lateral lymph node metastasis in PTC.

Park VY, Kim EK, Moon HJ, Yoon JH, Kwak JY.

Medicine (Baltimore). 2016 Jul;95(29):e4292. doi: 10.1097/MD.0000000000004292.

20.

The role of molecular markers and tumor histological type in central lymph node metastasis of papillary thyroid carcinoma.

Paulson L, Shindo M, Schuff K, Corless C.

Arch Otolaryngol Head Neck Surg. 2012 Jan;138(1):44-9. doi: 10.1001/archoto.2011.226.

PMID:
22249628

Supplemental Content

Support Center